Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)’s share price was down 15.5% on Tuesday . The company traded as low as $8.12 and last traded at $9.24. Approximately 1,016,024 shares changed hands during mid-day trading, an increase of 428% from the average daily volume of 192,494 shares. The stock had previously closed at $10.93.
A number of equities analysts recently weighed in on AGLE shares. ValuEngine raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Zacks Investment Research raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Tuesday, May 15th. Wells Fargo & Co cut Aeglea Bio Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, BMO Capital Markets initiated coverage on Aeglea Bio Therapeutics in a research note on Thursday, June 14th. They set an “outperform” rating and a $21.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $22.50.
The company has a market cap of $240.41 million, a price-to-earnings ratio of -4.83 and a beta of 0.03.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.10). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 57.15%. The business had revenue of $2.38 million for the quarter. research analysts forecast that Aeglea Bio Therapeutics Inc will post -1.8 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new position in Aeglea Bio Therapeutics during the 2nd quarter valued at about $438,000. Millennium Management LLC lifted its holdings in shares of Aeglea Bio Therapeutics by 542.2% during the 2nd quarter. Millennium Management LLC now owns 476,478 shares of the biotechnology company’s stock valued at $5,041,000 after buying an additional 402,288 shares during the last quarter. Orbimed Advisors LLC lifted its holdings in shares of Aeglea Bio Therapeutics by 26.9% during the 2nd quarter. Orbimed Advisors LLC now owns 1,865,524 shares of the biotechnology company’s stock valued at $19,737,000 after buying an additional 396,000 shares during the last quarter. Soros Fund Management LLC acquired a new stake in shares of Aeglea Bio Therapeutics during the 2nd quarter valued at about $2,184,000. Finally, SCP Investment LP acquired a new stake in shares of Aeglea Bio Therapeutics during the 2nd quarter valued at about $1,652,000. 66.77% of the stock is currently owned by institutional investors.
About Aeglea Bio Therapeutics (NASDAQ:AGLE)
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.